Jcr Pharmaceuticals Co., Ltd.

This study looks at the long-term safety and effectiveness of a drug called JR-141 for people with Hunter syndrome, a rare genetic disorder that affects many parts of the body. About 80 participants who completed an earlier study will continue treatment. Researchers will measure …

This phase 3 study tests JR-141, an enzyme replacement therapy designed to cross into the brain and treat Hunter syndrome (MPS II). About 86 participants receive the drug to see if it reduces harmful sugar buildup in spinal fluid and improves thinking skills. The goal is to slow …